Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease

被引:99
|
作者
Pothoven, Kathryn L. [1 ]
Norton, James E. [1 ]
Suh, Lydia A. [1 ]
Carter, Roderick G. [1 ]
Harris, Kathleen E. [1 ]
Biyasheva, Assel [1 ]
Welch, Kevin [2 ]
Shintani-Smith, Stephanie [2 ]
Conley, David B. [2 ]
Liu, Mark C. [3 ,4 ,5 ]
Kato, Atsushi [1 ]
Avila, Pedro C. [1 ]
Hamid, Qutayba [6 ,7 ]
Grammer, Leslie C., III [1 ]
Peters, Anju T. [1 ]
Kern, Robert C. [1 ]
Tan, Bruce K. [2 ]
Schleimer, Robert P. [1 ,2 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA
[3] Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD USA
[4] Johns Hopkins Asthma & Allergy Ctr, Div Pulm Med, Baltimore, MD USA
[5] Johns Hopkins Asthma & Allergy Ctr, Div Crit Care Med, Baltimore, MD USA
[6] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada
[7] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada
基金
美国国家卫生研究院;
关键词
Oncostatin M; epithelial barrier; neutrophils; chronic rhinosinusitis; atopic asthma; granulocyte-monocyte colony-stimulating factor; COLONY-STIMULATING FACTOR; CHRONIC RHINOSINUSITIS; NASAL POLYPS; RHEUMATOID-ARTHRITIS; PERSISTENT ASTHMA; TUMOR PROGRESSION; HUMAN MACROPHAGES; AP-1; ACTIVATION; M EXPRESSION; INFLAMMATION;
D O I
10.1016/j.jaci.2016.10.039
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: We have previously shown that oncostatin M (OSM) levels are increased in nasal polyps (NPs) of patients with chronic rhinosinusitis (CRS), as well as in bronchoalveolar lavage fluid, after segmental allergen challenge in allergic asthmatic patients. We also showed in vitro that physiologic levels of OSM impair barrier function in differentiated airway epithelium. Objective: We sought to determine which hematopoietic or resident cell type or types were the source of the OSM expressed in patients with mucosal airways disease. Methods: Paraffin-embedded NP sections were stained with fluorescence-labeled specific antibodies against OSM, GM-CSF, and hematopoietic cell-specific markers. Live cells were isolated from NPs and matched blood samples for flow cytometric analysis. Neutrophils were isolated from whole blood and cultured with the known OSM inducers GM-CSF and follistatin-like 1, and OSM levels were measured in the supernatants. Bronchial biopsy sections from control subjects, patients with moderate asthma, and patients with severe asthma were stained for OSM and neutrophil elastase. Results: OSM staining was observed in NPs, showed colocalization with neutrophil elastase (n = 10), and did not colocalize with markers for eosinophils, macrophages, T cells, or B cells (n = 3-5). Flow cytometric analysis of NPs (n = 9) showed that 5.1% +/- 2% of CD45(+) cells were OSM+, and of the OSM+ cells, 56% +/- 7% were CD16(+)Siglec-8(-), indicating neutrophil lineage. Only 0.6 +/- 0.4% of CD45(+) events from matched blood samples (n = 5) were OSM+, suggesting that increased OSM levels in patients with CRS was locally stimulated and produced. A majority of OSM+ neutrophils expressed arginase 1 (72.5% +/- 12%), suggesting an N2 phenotype. GM-CSF levels were increased in NPs compared with those in control tissue and were sufficient to induce OSM production (P < .001) in peripheral blood neutrophils in vitro. OSM+ neutrophils were also observed at increased levels in biopsy specimens from patients with severe asthma. Additionally, OSM protein levels were increased in induced sputum from asthmatic patients compared with that from control subjects (P < .05). Conclusions: Neutrophils are a major source of OSM-producing cells in patients with CRS and severe asthma.
引用
收藏
页码:1966 / +
页数:22
相关论文
共 11 条
  • [1] Oncostatin M is produced by neutrophils, and promotes epithelial barrier dysfunction in mucosal airways disease
    Pothoven, Kathryn L.
    Norton, James E.
    Suh, Lydia A.
    Carter, Roderick G.
    Welch, Kevin C.
    Shintani-Smith, Stephanie
    Conley, David B.
    Grammer, Leslie
    Peters, Anju T.
    Liu, Mark C.
    Kato, Atsushi
    Kern, Robert C.
    Tan, Bruce K.
    Schleimer, Robert P.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [2] Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease
    Pothoven, Kathryn L.
    Norton, James E.
    Hulse, Kathryn E.
    Suh, Lydia A.
    Carter, Roderick G.
    Rocci, Erin
    Harris, Kathleen E.
    Shintani-Smith, Stephanie
    Conley, David B.
    Chandra, Rakesh K.
    Liu, Mark C.
    Kato, Atsushi
    Gonsalves, Nirmala
    Grammer, Leslie C., III
    Peters, Anju T.
    Kern, Robert C.
    Bryce, Paul J.
    Tan, Bruce K.
    Schleimer, Robert P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (03) : 737 - +
  • [3] Oncostatin M promotes epithelial barrier dysfunction and is elevated in eosinophilic mucosal disease
    Pothoven, Kathryn
    Norton, James
    Suh, Lydia
    Carter, Roderick
    Hulse, Kathryn
    Liu, Mark
    Gonsalves, Nirmala
    Peters, Anju
    Harris, Kathleen
    Smith, Stephanie Shintani
    Conley, David
    Grammer, Leslie
    Kato, Atsushi
    Kern, Robert
    Bryce, Paul
    Tan, Bruce
    Schleimer, Robert
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [4] Oncostatin M Is Elevated in Mucosal Disease and May Mediate Epithelial Barrier Dysfunction in Vivo
    Pothoven, Kathryn L.
    Norton, James E.
    Suh, Lydia
    Carter, Roderick G.
    Hulse, Kathryn E.
    Rocci, Erin
    Gonsalves, Nirmala
    Liu, Mark C.
    Peters, Anju T.
    Harris, Kathleen E.
    Smith, Stephanie Shintani
    Conley, David B.
    Grammer, Leslie C.
    Kato, Atsushi
    Kern, Robert C.
    Bryce, Paul
    Tan, Bruce
    Schleimer, Robert P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB80 - AB80
  • [5] Oncostatin M promotes epithelial barrier dysfunction in patients with eosinophilic chronic rhinosinusitis with nasal polyps
    Wang, Bao-Feng
    Wang, Ying-Ying
    Lin, Hai
    Yi, Yun-Lan
    TISSUE BARRIERS, 2024,
  • [6] Serum oncostatin M predicts mucosal healing in Crohn's disease patients treated with infliximab
    Bertani, L.
    Antonioli, L.
    Fornili, M.
    Fornai, M.
    Tapete, G.
    Albano, E.
    Svizzero, G. Baiano
    Ceccarelli, L.
    Mumolo, M. G.
    Baglietto, L.
    Marchi, S.
    Blandizzi, C.
    Costa, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S406 - S406
  • [7] SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB
    Bertani, L.
    Antonioli, L.
    Fornili, M.
    Fornai, M.
    Tapete, G.
    Albano, E.
    Svizzero, Baiano G.
    Ceccarelli, L.
    Mumolo, M. G.
    Baglietto, L.
    Marchi, S.
    Blandizzi, C.
    Costa, F.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S125 - S126
  • [8] SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB
    Bertani, Lorenzo
    Antonioli, Luca
    Fornili, Marco
    Fornai, Matteo
    Tapete, Gherardo
    Svizzero, Giovanni Baiano
    Ceccarelli, Linda
    Mumolo, Gloria M.
    Bellini, Massimo
    Baglietto, Laura
    Marchi, Santino
    Blandizzi, Corrado
    Costa, Francesco
    GASTROENTEROLOGY, 2020, 158 (06) : S1030 - S1030
  • [9] Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
    Bertani, Lorenzo
    Fornai, Matteo
    Fornili, Marco
    Antonioli, Luca
    Benvenuti, Laura
    Tapete, Gherardo
    Svizzero, Giovanni Baiano
    Ceccarelli, Linda
    Mumolo, Maria Gloria
    Baglietto, Laura
    de Bortoli, Nicola
    Bellini, Massimo
    Marchi, Santino
    Costa, Francesco
    Blandizzi, Corrado
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (02) : 284 - 291
  • [10] Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab
    Appleton, Laura
    Day, Andrew S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (06) : 1080 - 1081